Company profile
Dicot Pharma company profile
Dicot Pharma develops LIB-01 to become a new modern potency drug for the global market. The goal is to develop a completely new generation potency drugs that surpass currently available treatments. With a longer duration of action, fewer adverse effects, and a differentiated mode of action, Dicot Pharma aims to significantly improve the treatment of erectile dysfunctions and provide affected men and couples with a better quality of life. The company's lead candidate, LIB-01, is in clinical phase 2a. Ticker Nasdaq First North Stockholm: "DICOT"
Business identity
- Website
- https://www.dicotpharma.com/
- Contact email
- [email protected]
- Phone number
- +46 (0) 72-502 1010
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $0+
- Founded
- 2015-01-01, Year
Headquarters
- Headquarters
- Kholbon, Zabaykalskiy (Transbaikal) Kray, Russia
- Postal code
- 753 21
- Country code
- RU
- Continent
- Europe